Selected Publications / Posters
Monika Chabicovsky and her team are authors of several scientific publications in peer-reviewed journals and contributed to international patent applications.
- Palmeirim, MS., Specht S., Scandale, I., Gander-Meisterernst, I., Chabicovsky, M., Keiser, J., 2021. Preclinical and Clinical Characteristics of the Trichuricidal Drug Oxantel Pamoate and Clinical Development Plans: A Review. Drugs. 2021
Apr 30.
- Abstract at 2019 ACR/ARP Annual Meeting: Senter, R., Boyce, R., Chabicovsky, M., Walsh Martin, E., Langevin-Carpentier, G., Bodick, N., 2019. The Rat Homolog to FX201, a Gene Therapy in Development for the Treatment of Osteoarthritis,
Demonstrates Dose-Dependent Decreases in the Severity of Cartilage and Bone Lesions Following Anterior Cruciate Ligament Transection. Atlanta, GA, USA, 8-13 November 2019.
- Wuschko S, Gugerell A, Chabicovsky M, Hofbauer H, Laggner M, Erb M, Ostler T, Peterbauer A, Suessner S, Demyanets S, Leuschner J, Moser B, Mildner M, Ankersmit HJ, 2019. Toxicological testing of allogeneic secretome derived from peripheral
mononuclear cells (APOSEC): a novel cell-free therapeutic agent in skin disease. Sci Rep. 2019 Apr 3;9(1):5598.
- Chabicovsky, M., Winkler, S., Soeberdt, M., Kilic, A., Masur, C., Abels, C., 2019. Pharmacology, toxicology and clinical safety of glycopyrrolate. Toxicol and Appl Pharmacol, 370,154-169
- Abstract at American College of Toxicology 38th Annual Meeting: Boulay, I., Wong, K., Fodor, W., Chabicovsky, M., Günzl, A., Götz, R., Yee Hung, S., Larivee, A., Haruna, J., Bujold, K., Wierzbicki, W., Authier, S., 2017.Selection of positive
control cells for use in cell therapy tumorigenicity assessment in NOD/SCID/IL2Rgnull (NSG) mice subjected to immunoablative whole body Co-60 irradiation. Palm Springs. USA, 5-8 November 2017.
- Thurner, G.C., Chabicovsky, M., Abdelmoez, A., Debbage, P., 2016. Targeted Drugs and Nanomedicine: Present and Future. Frontiers in Medicinal Chemistry 8.
- Poster Presentation at ESGCT and ISSCR Collaborative Congress: Hebar (Günzl), A., Chabicovsky, M. Non-clinical development of advanced therapies: potential for a tightrope walk between science and regulatory requirements. Florence, Italy,
18-21 October 2016.
- Hebar, A., Chabicovsky, M., 2015a. Challenges of and Recommendations for Outsourcing Early Non-Clinical Development Activities. Pharm. Ind. 77, 1296-1300.
- Hebar, A., Chabicovsky, M., 2015b. Nonclinical Development of ATMPs - Challenges and Regulatory Strategy in the EU (Part 1). Forum Institut - Regulatory Affairs Newsletter April 2015.
- Hebar, A., Chabicovsky, M., 2015c. Nonclinical Development of ATMPs - Challenges and Regulatory Strategy in the EU (Part 2). Forum Institut - Regulatory Affairs Newsletter June 2015.
- Hebar, A., Koller, C., Seifert, J.M., Chabicovsky, M., Bodenteich, A., Bernkop-Schnurch, A., Grassauer, A., Prieschl-Grassauer, E., 2015. Non-clinical safety evaluation of intranasal iota-carrageenan. PloS one 10, e0122911.
- Chabicovsky, M., Prieschl-Grassauer, E., Seipelt, J., Muster, T., Szolar, O.H., Hebar, A., Doblhoff-Dier, O., 2010. Pre-clinical safety evaluation of pyrrolidine dithiocarbamate. Basic & clinical pharmacology & toxicology 107, 758-767.
- Chabicovsky, M., Ryle, P., 2006. Non-clinical development of cancer vaccines: regulatory considerations. Regul Toxicol Pharmacol 44, 226-237.